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PROs represent an important aspect of a patient’s health status assessment that come without
bias of the healthcare provider. PROs allow clinicians to evaluate the effects of illness and
medical treatments by quantifying symptoms that are by definition, subjective, and therefore,
unmeasured by medical devices. PROs can include both general and disease-specific quality
of life. Although several bladder cancer-specific HRQOL instruments exist, there is only one
with a Japanese translation – FACT-Bl – previously validated by Hinotsu et al.1 However,
assessment with FACT-Bl is limited to systemic symptoms, as it lacks items specific to uri-
nary, bowel and sexual function, which are important components for assessing bladder can-
cer patients. In the previous report, the Japanese version of the EPIC was used to evaluate
HRQOL after bladder preservation therapy instead of FACT-Bl.2 Although reasonable and
acceptable outcomes were obtained, further assessment needs to be carried out. That is
because EPIC was designed for male prostate cancer patients. The BCI was developed and
validated in the USA to assess the severity of symptoms for urinary, bowel and sexual
domains (Appendix S1).3 The BCI was intended to be a sex- and diversion-neutral instrument
for patients treated with cystectomy, transurethral resection with/without intravesical therapy
and radiation. The BCI has been translated and validated into French, Spanish, Arabian and
Hungarian languages.4 Furthermore, the BCI was recently used to evaluate function HRQOL
among patients treated for bladder cancer in a comparative study.5
According to the previously reported method for cross-cultural translation of HRQOL, we
carried out a multistage procedure to develop a preliminary Japanese version after permission
from the original developer (JT Wei) to translate and use the BCI.6 Two Japanese translations
of the BCI were carried out independently by two native Japanese physicians who had Eng-
lish as a second language. Subsequently, the reconciled translation was back-translated into
English by a native English professional translator. Of 34 items in the BCI, 22 items over-
lapped with the EPIC, and therefore, the Japanese version of EPIC is applied with the permis-
sion of JT Wei and Y Kakehi.7 The two forms of the BCI (original and backward translation)
were compared, and qualities lost in the translation due to cultural nuances were discussed
and resolved in a consensus meeting with JT Wei, resulting in the draft Japanese BCI version.
This draft version was then reviewed by laypersons fluent in Japanese to develop a linguisti-
cally valid, easy-to-understand Japanese version (Appendix S2; Fig. S1).
Statistical validation was undertaken. The reliability of the Japanese version of the BCI
was evaluated for internal consistency using Cronbach’s alpha coefficient for each domain of
the BCI. All statistical tests were carried out using the JMP software (SAS Institute, Cary,
NC, USA). After obtaining approval from the institutional review board (015-0504), cognitive
interviews and pilot testing of the BCI were carried out with 14 patients (nine males and five
females), with a mean age of 69.5 years (range 47–93 years) and disease duration of
31.5 months (range 11–272 months). Of these patients, eight patients underwent transurethral
resection of bladder tumor and six patients underwent radical cystectomy (among them two
patients had ileal conduit, two had neobladder, one had cutaneous ureterostomy and one had
continent catheterizable pouch). The Cronbach’s alpha coefficients were 0.86, 0.72 and 0.92
for the urinary domain, bowel domain and sexual domain, respectively. These were all in the
range of 0.70–0.95, indicating high internal consistency (Table 1). The average length of the
interview was 30 min. Most patients completed the questionnaire without difficulty, and fur-
ther modifications were unnecessary. In a final consensus review that included urologists and
clinical psychologists, the Japanese version was finalized (Appendix S1). This Japanese ver-
sion of the BCI has demonstrable face validity and reliability. It can be used for evaluating
HRQOL among Japanese patients with bladder cancer and for cross-cultural comparisons.
The copyright of the BCI resides strictly with The University of Michigan. The University of
Michigan has granted the right to use the Japanese version of the BCI to healthcare providers
who do not obtain profit using this.
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Figure S1. Multistep procedures to develop the Japanese ver-
sion of the BCI.
Appendix S1. The original English version of the BCI.
Appendix S2. The Japanese version of the BCI. The copy-
right of the BCI resides strictly with The University of
Michigan. The University of Michigan has granted the right
to use the Japanese version of the BCI to healthcare providers
who do not obtain profit by using this.
Table 1 Domain-specific characteristics of the Japanese version of the
BCI
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